



iridium
kankernetwerk

- AZ Klina**
Brasschaat
- AZ Monica**
Antwerpen - Deurne
- AZ Nikolaas**
Sint-Niklaas,
Partner AZ Lokeren
- AZ Sint-Jozef**
Malle
- GZA Ziekenhuizen**
Antwerpen - Mortsel - Wilrijk
- UZA**
Edegem
- ZNA**
Antwerpen - Merksem

**Sparen van gezonde weefsels
d.m.v. innovatieve radiotherapie**

Piet Dirix MD, PhD

Radiotherapie-Oncologie



Iridium Kankernetwerk

www.iridiumkankernetwerk.be




Gray = physical unit of radiation

- Dose = absorbed E/mass
- Gray = unit of absorbed E (Joule/kg)
- 1 Gy = 2×10^5 ionization events/cell
(1% in DNA)





```


    graph TD
      Cell((Cell)) --> Repair[repair]
      Cell --> Incorrect[incorrect repair]
      Cell --> NoRepair[no repair]
      Repair --> Survival[cell survival]
      Incorrect --> Mutation[mutation]
      Incorrect --> CellDeath[cell death]
      Mutation --> Cancer[cancer]
  
```




Fractionation








3 x 3.3 Gy




5 x 2 Gy



The biological basis of fractionation


DNA DAMAGE	DNA REPAIR SYSTEM
	<p>DIRECT REVERSAL</p>
	<p>MISMATCH REPAIR</p>
	<p>NUCLEOTIDE EXCISION REPAIR</p>
	<p>RECOMBINATIONAL REPAIR</p>
	<p>BASE EXCISION REPAIR</p>






Probability of Tumor Control (green curve)
Probability of Normal Tissue Damage (red curve)



Difference of DNA Repair
Tumour Cells < Healthy Tissue

"Fractionation"










Evolution of radiotherapy techniques

2D-RT 1990 3D-CRT 2000 IMRT 2010 VMAT


2D 3D-CRT VMAT

Radiorectitis = dose-limiting toxicity (DLT)




Intensity-modulated radiotherapy (IMRT)


Prostate
Rectum



Multileaf collimator (MLC)



ABSOLUT DMLC.




SEER database

Table 3. Unadjusted and Propensity-Model Adjusted Outcomes for IMRT vs CRT

Outcome per 100 Person-Years	Unadjusted						Adjusted ^a							
	CRT (n = 6310)			IMRT (n = 6666)			CRT (n = 6478)			IMRT (n = 6438)				
	Total Events	100 Person-Years	Rate	Total Events	100 Person-Years	Rate	Total Events	100 Person-Years	Rate	Total Events	100 Person-Years	Rate	IMRT vs CRT, Rate Ratio (95% CI)	
Gastrointestinal events														
Procedures (including colonoscopy)	3187	195	16.3	2940	167	17.6	1.08 (1.03-1.13)	2989	180	16.6	3011	177	17.0	1.02 (0.97-1.07)
Diagnoses	2946	212	13.9	2450	182	13.5	0.97 (0.92-1.02)	2828	192	14.7	2594	194	13.4	0.91 (0.86-0.96)
Urinary nonincontinence events														
Procedures	564	293	1.9	439	234	1.9	0.98 (0.86-1.11)	493	260	1.9	483	257	1.9	0.99 (0.87-1.12)
Diagnoses	2003	248	8.1	1747	199	8.8	1.09 (1.02-1.16)	1941	220	8.8	1869	214	8.8	0.99 (0.93-1.06)
Urinary incontinence events														
Procedures	1904	246	7.7	1854	194	9.5	1.23 (1.16-1.32)	1867	219	8.5	1888	211	8.9	1.05 (0.98-1.12)
Diagnoses	970	283	3.4	785	226	3.5	1.01 (0.92-1.11)	917	251	3.7	858	249	3.5	0.94 (0.86-1.04)
Erectile dysfunction events														
Procedures	202	303	0.7	200	240	0.8	1.25 (1.03-1.52)	224	268	0.8	200	265	0.8	0.90 (0.75-1.09)
Diagnoses	1186	265	4.5	1342	208	6.5	1.44 (1.33-1.56)	1239	235	5.3	1342	228	5.9	1.12 (1.03-1.20)
Hip fracture	301	302	1.0	186	240	0.8	0.78 (0.65-0.93)	272	267	1.0	209	265	0.8	0.78 (0.65-0.93)
Additional cancer therapy	896	302	3.0	575	249	2.3	0.78 (0.70-0.87)	839	270	3.1	677	270	2.5	0.81 (0.73-0.89)

Abbreviations: CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy.
^aRates shown are adjusted for the variables presented in Tables 1 and 2, using propensity scores implemented by inverse probability of treatment weighting.



Sheets N.C. et al. JAMA 2012.

VMAT



Advantages over "conventional" IMRT:



- **Fast (< 2 minutes):**
 - Limits intra-fraction motion
 - Increases patient comfort
 - Reduces waiting lists
 - Probable radiobiological advantage
- **Highly conformal: modulate at every angle**
 - Gantry speed
 - MLC aperture shape
 - Dose rate





Image-guided radiotherapie (IGRT)




IGRT = making sure that treatment is delivered as planned




Dawson J. et al. J Clin Oncol 2007.



kV-MV "matching" on bony anatomy



kV-MV "matching" on fiducial markers



CB-CT "matching" on soft tissue




MR "matching" on MR-Linac


MRIdian (ViewRay)



Unity (Elekta-Philips)



Australian MR-Linac program




University of Alberta




Dirix P. et al. Semin Radiat Oncol 2014.

MR-LINACS will allow for true soft tissue matching

Linac – Cone-beam CT



MR-LINAC




- | | | |
|---|--|---|
| ✘ | Eliminate X-ray radiation | ✔ |
| ✘ | Don't use registration markers | ✔ |
| ✘ | Differentiate between soft tissues and tumor | ✔ |
| ✘ | Ability to locate, target and track the tumor directly | ✔ |



Dirix P. et al. Semin Radiat Oncol 2014.

Ultimate combination of IMRT and IGRT: SABR



1. GTV delineated on MRI and/or PET.
2. No or limited CTV.
3. PTV margins < 0,5 cm.
4. Good quality daily IGRT is essential.
5. Extremely hypofractionated.

SABR = stereotactic ablative body radiotherapy




Hypofractionation

Target volume	Previous fractionation	Current fractionation	SABR alternative
Brain tumors	30x 2,0 Gy	15x 2,67 Gy	SRS
Breast cancer	25x 2,0 Gy	15x 2,67 Gy	APBI
Lung cancer	30-33x 2,0 Gy	16-20x 2,75 Gy	Lung SBRT
Rectal cancer	25x 1,8 Gy	5x 5,0 Gy	-
Prostate cancer	37-40x 2,0 Gy	20x 3,0 Gy	5x 7,0 Gy
Bladder cancer	33x 2,0 Gy	15x 2,75 Gy	-
Bone mets	10x 3,0 Gy	1x 8,0 Gy	1x 16,0 Gy
...			



Cured in a FLASH?



Durante M. et al. Br J Radiol 2018.

Conclusions

- Radiation delivery already has **potential ≤ 1 mm accuracy**.
- From a **physics** point of view, the greatest improvements can be expected from:
 - **Imaging**, both before and during RT, allowing us to see and therefore hit the target more precisely.
 - Experiments in **ultra-high dose rate (FLASH)** radiotherapy.
- From a **biology** point of view, we should probably invest in:
 - More precise **radiosensitization** (e.g. TGF- β).
 - Individualized **dose prescription**.

